Given the expression of PLK1 by AML-NS8 cells, we used these cells in vitro as target for the cytotoxic activity of our proprietary PLK1 inhibitor NMS-P937 [14], [23], in comparison with cytarabine and doxorubicin. Here, PLK1 is linked to acute myeloid leukemia.